Market Research Logo

Narcolepsy- Epidemiology Forecast to 2027

DelveInsight’s ‘Narcolepsy - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Narcolepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Narcolepsy Epidemiology
The Narcolepsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Narcolepsy are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Narcolepsy Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, narcolepsy with and without cataplexy prevalent cases, prevalent cases by manifestations, diagnosed cases, age-specific diagnosed cases) scenario of Narcolepsy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, total prevalent population of Narcolepsy in 7 major markets are about 507,138 in 2016.

Report Scope
• The report covers detailed overview of Narcolepsy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Narcolepsy in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by narcolepsy with and without cataplexy, cases by clinical manifestation and age-specific diagnosed cases in 7MM

Key strengths
• 10 Year Forecast of Narcolepsy epidemiology
• 7MM Coverage
• Total Prevalent Cases of Narcolepsy
• Prevalent Cases according to segmentation: Narcolepsy with and without cataplexy, cases by clinical manifestation and age-specific diagnosed cases
• Diagnosed cases of Narcolepsy

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population


1. Key Insights
2. Disease Background and Overview: Narcolepsy
2.1. Introduction
2.2. Signs and Symptoms
2.3. Complications
2.4. Pathophysiology
2.5. Etiology
2.6. Risk Factors
2.7. Diagnosis
2.8. Treatment
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. Population and Forecast Parameters
4. 7MM Total Prevalent Patient Population of Narcolepsy
4.1. United States
4.1.1. Prevalent Patient Population of Narcolepsy in the United States
4.1.2. Narcolepsy with and without Cataplexy Cases
4.1.3. Prevalent Cases by Clinical Manifestation
4.1.4. Diagnosed Cases of Narcolepsy
4.1.5. Age-Specific Diagnosed Cases of Narcolepsy
4.2. Germany
4.2.1. Prevalent Population of Narcolepsy
4.2.2. Narcolepsy cases with and without Cataplexy
4.2.3. Prevalent Cases by Clinical Manifestation
4.2.4. Diagnosed Cases of Narcolepsy
4.2.5. Age-Specific Diagnosed Cases of Narcolepsy
4.3. France
4.3.1. Prevalent Population of Narcolepsy
4.3.2. Narcolepsy cases with and without Cataplexy
4.3.3. Prevalent Cases by Clinical Manifestation
4.3.4. Diagnosed Cases of Narcolepsy
4.3.5. Age-Specific Diagnosed Cases of Narcolepsy
4.4. Italy
4.4.1. Prevalent Population of Narcolepsy in Italy
4.4.2. Narcolepsy cases with and without Cataplexy
4.4.3. Prevalent Cases by Clinical Manifestation
4.4.4. Diagnosed Cases of Narcolepsy
4.4.5. Age-Specific Diagnosed Cases of Narcolepsy
4.5. Spain
4.5.1. Prevalent Population of Narcolepsy
4.5.2. Narcolepsy cases with and without Cataplexy
4.5.3. Prevalent Cases by Clinical Manifestation
4.5.4. Diagnosed Cases of Narcolepsy
4.5.5. Age-Specific Diagnosed Cases of Narcolepsy
4.6. United Kingdom
4.6.1. Prevalent Cases of Narcolepsy
4.6.2. Narcolepsy cases with and without Cataplexy
4.6.3. Prevalent Cases by Clinical Manifestation
4.6.4. Diagnosed Cases of Narcolepsy
4.6.5. Age-Specific Diagnosed Cases of Narcolepsy
4.7. Japan
4.7.1. Prevalent Population of Narcolepsy
4.7.2. Narcolepsy cases with and without Cataplexy
4.7.3. Prevalent Cases by Clinical Manifestation
4.7.4. Diagnosed Cases of Narcolepsy
4.7.5. Age-Specific Diagnosed Cases of Narcolepsy
5. Market Drivers
6. Market Barriers
7. Appendix
8. Report Methodology
8.1. Sources Used
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
Table 1 Total Prevalent Patient Population of Narcolepsy in the 7MM (2016-2027)
Table 2 Prevalent Cases of Narcolepsy in the United States (2016-2027)
Table 3 Narcolepsy with and without Cataplexy Cases in the United States (2016-2027)
Table 4 Prevalent Cases of Narcolepsy by Clinical Manifestations in the United States (2016-2027)
Table 5 Diagnosed Cases of Narcolepsy in the United States (2016-2027)
Table 6 Age-Specific Diagnosed Cases of Narcolepsy in United States (2016-2027)
Table 7 Prevalent Cases of Narcolepsy in Germany (2016-2027)
Table 8 Narcolepsy with and without Cataplexy Cases in Germany (2016-2027)
Table 9 Prevalent Cases of Narcolepsy by Clinical Manifestations in Germany (2016-2027)
Table 10 Diagnosed Cases of Narcolepsy in Germany (2016-2027)
Table 11 Age-Specific Diagnosed Cases of Narcolepsy in Germany (2016-2027)
Table 12 Prevalent Cases of Narcolepsy in France (2016-2027)
Table 13 Narcolepsy with and without Cataplexy cases in France (2016-2027)
Table 14 Prevalent Cases of Narcolepsy by Clinical Manifestations in France (2016-2027)
Table 15 Diagnosed Cases of Narcolepsy in France (2063-2027)
Table 16 Age-Specific Diagnosed Cases of Narcolepsy in France (2016-2027)
Table 17 Prevalent Population of Narcolepsy in Italy (2016-2027)
Table 18 Narcolepsy with and without Cataplexy cases in Italy (2016-2027)
Table 19 Prevalent Cases of Narcolepsy by Clinical Manifestations in Italy (2016-2027)
Table 20 Diagnosed Cases of Narcolepsy in Italy (2016-2027)
Table 21 Age-Specific Diagnosed Cases of Narcolepsy in Italy (2016-2027)
Table 22 Prevalent Cases of Narcolepsy in Spain (2016-2027)
Table 23 Narcolepsy with and without Cataplexy Cases in Spain (2016-2027)
Table 24 Prevalent Cases of Narcolepsy by Clinical Manifestations in Spain (2016-2027)
Table 25 Diagnosed Cases of Narcolepsy in Spain (2016-2027)
Table 26 Age-Specific Diagnosed Cases of Narcolepsy in Spain (2016-2027)
Table 27 Prevalent Cases of Narcolepsy in the United Kingdom (2016-2027)
Table 28 Narcolepsy with and without Cataplexy cases in the United Kingdom (2016-2027)
Table 29 Prevalent Cases of Narcolepsy by Clinical Manifestations in United Kingdom (2016-2027)
Table 30 Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2027)
Table 31 Age-Specific Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2027)
Table 32 Prevalent Cases of Narcolepsy in Japan (2016-2027)
Table 33 Narcolepsy with and without Cataplexy cases in Japan (2016-2027)
Table 34 Prevalent Cases of Narcolepsy by Clinical Manifestations in Japan (2016-2027)
Table 35 Diagnosed Cases of Narcolepsy in Japan (2016-2027)
Table 36 Age-Specific Diagnosed Cases of Narcolepsy in Japan (2016-2027)
Figure 1: Complications of Narcolepsy
Figure 2: Pathophysiology of Narcolepsy
Figure 3: Prevalent Cases of Narcolepsy in the United States (2016-2027)
Figure 4: Narcolepsy with and without Cataplexy Cases in the United States (2016-2027)
Figure 5: Prevalent Cases of Narcolepsy by Clinical Manifestations in the United States (2016-2027)
Figure 6: Diagnosed Cases of Narcolepsy in the United States (2016-2027)
Figure 7: Age-Specific Diagnosed Cases of Narcolepsy in the United States (2016-2027)
Figure 8:Prevalent Cases of Narcolepsy in Germany (2016-2027)
Figure 9: Narcolepsy with and without Cataplexy Cases in Germany (2016-2027)
Figure 10: Prevalent Cases of Narcolepsy by Clinical Manifestations in Germany (2016-2027)
Figure 11: Diagnosed Cases of Narcolepsy in Germany (2016-2027)
Figure 12: Age-Specific Diagnosed Cases of Narcolepsy in Germany (2016-2027)
Figure 13: Prevalent Cases of Narcolepsy in France (2016-2027)
Figure 14: Narcolepsy with and without Cataplexy cases in France (2016-2027)
Figure 15: Prevalent Cases of Narcolepsy by Clinical Manifestations in France (2016-2027)
Figure 16: Diagnosed Cases of Narcolepsy in France (2016-2027)
Figure 17: Age-Specific Diagnosed Cases of Narcolepsy in France (2016-2027)
Figure 18: Prevalent Population of Narcolepsy in Italy (2016-2027)
Figure 19: Narcolepsy with and without Cataplexy cases in Italy (2016-2027)
Figure 20: Prevalent Cases of Narcolepsy by Clinical Manifestations in Italy (2016-2027)
Figure 21: Diagnosed Cases of Narcolepsy in Italy (2016-2027)
Figure 22: Age-Specific Diagnosed Cases of Narcolepsy in Italy (2016-2027)
Figure 23: Prevalent Cases of Narcolepsy in Spain (2016-2027)
Figure 24: Narcolepsy with and without Cataplexy Cases in Spain (2016-2027)
Figure 25: Prevalent Cases of Narcolepsy by Clinical Manifestations in Spain (2016-2027)
Figure 26: Diagnosed Cases of Narcolepsy in Spain (2016-2027)
Figure 27: Age-Specific Diagnosed Cases of Narcolepsy in Spain (2016-2027)
Figure 28: Prevalent Cases of Narcolepsy in the United Kingdom (2016-2027)
Figure 29: Narcolepsy with and without Cataplexy cases in the United Kingdom (2016-2027)
Figure 30: Prevalent Cases of Narcolepsy by Clinical Manifestations in the United Kingdom (2016-2027)
Figure 31: Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2027)
Figure 32: Age-Specific Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2027)
Figure 33: Prevalent Population of Narcolepsy in Japan (2016-2027)
Figure 34: Narcolepsy with and without Cataplexy cases in Japan (2016-2027)
Figure 35: Prevalent Cases of Narcolepsy by Clinical Manifestations in Japan (2016-2027)
Figure 36: Total Prevalent Population of Narcolepsy in Japan (2016-2027)
Figure 37: Age-Specific Diagnosed Cases of Narcolepsy in Japan (2016-2027)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report